High Lipoprotein(a) Symptoms: Causes, Signs & What to Do

Lipoprotein(a) [Lp(a)] is almost entirely genetically determined, cannot be lowered by diet or exercise, and doubles the risk of premature heart attack and stroke -- yet most people are never tested. This page covers what high Lp(a) means, why it's dangerous, and what can actually be done about it.

Published

April 23, 2026

Last updated

September 22, 2026

Read time

8 min read

Medically reviewed by

Rhonda Collins, FNP-C

Share

Copy link

High lipoprotein(a) produces no direct symptoms. Nothing about the level itself can be felt, which is why it is found on a blood test rather than through how you feel. What gets noticed, often decades later, are the conditions Lp(a) accelerates: heart attack, ischemic stroke, peripheral arterial disease, and calcific aortic valve disease. Lipoprotein(a), written Lp(a) and often typed LPA in search results and lab portals, is a modified form of LDL carrying an extra protein called apolipoprotein(a); strictly, LPA is the gene that codes for that protein rather than a name for the particle. Your level is set almost entirely by genetics and is largely unaffected by diet, exercise, or most lipid-lowering medications. Approximately 20-25% of the global population has Lp(a) above 50 mg/dL, the widely used high-risk threshold, and most of them are unaware because Lp(a) is not routinely included in standard lipid panels. See the Lipoprotein(a) biomarker overview for measurement details and the difference between mg/dL and nmol/L units.

What High Lipoprotein(a) Means

Lp(a) drives cardiovascular disease through two distinct mechanisms:

1. LDL-like atherogenicity — Lp(a) is taken up by artery walls, oxidized, and incorporated into atherosclerotic plaques, similar to LDL but with higher affinity for vessel walls
2. Procoagulant activity — the apo(a) protein structurally resembles plasminogen and competitively inhibits plasminogen binding, impairing fibrinolysis (the body’s clot-dissolving system); this explains why high Lp(a) is associated with clot-triggered events

Additionally, Lp(a) promotes calcific aortic valve disease — the protein accumulates in the valve leaflets, accelerating calcification — a unique risk not shared by LDL.

Symptoms of High Lipoprotein(a)

A high Lp(a) result is not something you can feel. The particle circulates without irritating tissue, raising blood pressure, or changing any function you would notice, so there is no level at which the number produces sensations. The CDC states plainly that many people with high Lp(a) have no symptoms. The harm accumulates quietly inside artery walls and the aortic valve over decades.

The honest answer to “what are the early warning signs of high Lp(a)” is that the level has none. There are only warning signs of the disease it accelerates, and by the time those appear the process is already established. All clinical consequences come from those long-term effects:

• Premature heart attack — Lp(a) roughly doubles the risk of myocardial infarction; events can occur in people in their 30s-40s with no other traditional risk factors
• Ischemic stroke — from both atherosclerotic disease and from the procoagulant mechanism
• Peripheral arterial disease — claudication and non-healing wounds from lower limb atherosclerosis
• Recurrent cardiovascular events — high Lp(a) is associated with worse outcomes even in people already on statin therapy, because Lp(a) is not reduced by statins
• Calcific aortic stenosis — progressive heart valve narrowing, presenting in later decades as exertional dyspnea, angina, and syncope

The signs worth acting on are those of the conditions, not of a lab value: chest pressure, tightness, or pain on exertion that eases with rest; cramping calf, thigh, or buttock pain while walking, or a lower-limb wound that will not heal; sudden one-sided weakness, facial droop, or difficulty speaking, which is a stroke or transient ischemic attack and needs emergency care; and breathlessness on exertion, light-headedness, or fainting, which can point to a narrowing aortic valve. Each is a sign of established disease, not an early signal of the Lp(a) number.

Fatigue is not a recognized symptom of elevated Lp(a). Tiredness has many causes and an Lp(a) result does not explain it, so persistent fatigue is worth investigating on its own terms.

Family history clues that suggest high Lp(a):

• A first-degree relative with a heart attack before age 55 in men or 65 in women
• A family history of aortic valve replacement or aortic stenosis
• Persistently elevated cardiovascular risk despite optimal LDL and lifestyle

What Causes High Lipoprotein(a)

For almost everyone with a high result, the cause is inheritance: the level was set at birth, not caused by anything you did, and it did not creep up over the years.

• Genetics (primary cause) — Lp(a) levels are 80-90% heritable; the LPA gene determines apo(a) isoform size; shorter isoforms are produced more rapidly and associate with higher Lp(a) levels
• Autosomal codominant inheritance — both alleles are expressed; a child of a parent with high Lp(a) has a 50% chance of inheriting the high-Lp(a) allele
• Post-menopause — estrogen suppresses Lp(a) production; after menopause, Lp(a) often rises by 20-30%
• Kidney disease — reduced renal clearance and increased hepatic production raise Lp(a)
• Hypothyroidism — thyroid hormone affects Lp(a) metabolism; hypothyroidism can raise Lp(a)

What does NOT significantly lower Lp(a): statins, fibrates, diet modification, aerobic exercise.

The LPA gene carries a repeated segment called “kringle IV type 2”, and the number of copies inherited varies widely. Fewer repeats build a shorter apo(a) protein, which the liver releases more readily, so it circulates at a higher concentration; more repeats build a longer protein that is secreted less efficiently, giving a lower level. One copy comes from each parent and both are expressed, so a result reflects the pair. The 2022 European Atherosclerosis Society consensus statement puts the genetic contribution above 90%.

That is also why the level barely moves. The same consensus statement recommends measuring Lp(a) at least once in adults, and the American College of Cardiology’s 2023 update notes levels typically do not change after about 5 years of age except during significant inflammation, liver disease, or kidney disease. A result does not need routine repeating.

The secondary causes modify an inherited level rather than create a high one, and the reported effects differ in size and in certainty. The menopause figure above is the most quoted but is not settled: the European Atherosclerosis Society classes menopause itself as having none-to-minimal effect on Lp(a), and a meta-analysis found no significant difference once pre- and postmenopausal women were matched for age, so part of the reported rise may reflect ageing. Kidney disease can raise Lp(a) substantially, with a three- to five-fold increase reported in nephrotic syndrome and around two-fold in people on peritoneal dialysis. Hypothyroidism raises it more modestly, with thyroid hormone replacement reported to lower Lp(a) by 5% to 20%. In each case the underlying condition is what gets treated.

Median Lp(a) also differs by population. The CDC states that high Lp(a) occurs in people of all races and ethnicities but appears to be more common in Black people, and the European Atherosclerosis Society reports UK Biobank medians rising across Chinese, White, South Asian, and Black participants (16, 19, 31, and 75 nmol/L). The risk threshold itself is not adjusted by ancestry.

Normal Lipoprotein(a) Levels

Note: Lp(a) can also be reported in nmol/L. The 50 mg/dL threshold corresponds to approximately 100-125 nmol/L, but the conversion varies by assay.

When to See Your Care Team

Book a 1:1 consultation with your care team for Lp(a) above 50 mg/dL, particularly with a family history of premature cardiovascular disease. Since Lp(a) itself cannot be lowered by lifestyle, the focus shifts to aggressively reducing all other modifiable risk factors: target LDL below 70 mg/dL, control blood pressure and blood glucose, eliminate smoking. PCSK9 inhibitors modestly lower Lp(a) by 20-30%. Dedicated RNA therapies targeting Lp(a) specifically are in late-stage clinical trials.

Frequently Asked Questions

Does high Lp(a) cause fatigue, chest pain, or any other symptom?

No. Lp(a) cannot be felt at any level, and fatigue in particular is not a recognized symptom of a high result. Symptoms that do occur in people with high Lp(a), such as exertional chest pressure or leg pain while walking, come from established cardiovascular disease rather than the level itself, and need evaluation in their own right.

Do Lp(a) levels change over time, and should I retest?

Not meaningfully for most adults. Because the level is genetically set, the European Atherosclerosis Society recommends measuring Lp(a) at least once in adulthood rather than tracking it, and the American College of Cardiology notes levels are typically stable after early childhood apart from significant inflammation, liver disease, or kidney disease. A repeat is worth discussing if one of those applies, not as routine monitoring.

Can exercise or diet lower Lp(a)?

No — not meaningfully. Lp(a) is genetically determined and does not respond to diet, aerobic exercise, or most lipid-lowering therapies. This is a core difference from LDL. A Mediterranean diet, weight loss, or statin use will lower LDL significantly but leave Lp(a) essentially unchanged. Screening and aggressive management of all other cardiovascular risk factors is the current approach.

Do statins make Lp(a) worse?

Some studies show statins can paradoxically raise Lp(a) by 10-20%. The clinical significance is debated — statins still substantially reduce cardiovascular risk in high-Lp(a) patients by lowering LDL, and the net benefit is clear for individuals with combined elevated LDL and Lp(a).

Should family members be tested if I have high Lp(a)?

Yes. Because Lp(a) is codominant and highly heritable, first-degree relatives (parents, siblings, children) have a 50% probability of inheriting the same high-Lp(a) allele. The European Atherosclerosis Society recommends cascade testing of family members when an index case with Lp(a) above 50 mg/dL is identified.

What new treatments are coming?

Two RNA-targeting therapies — pelacarsen (antisense oligonucleotide) and olpasiran (siRNA) — have shown 80-90% reductions in Lp(a) in Phase 2 and Phase 3 trials. Outcome data for cardiovascular event reduction are expected from the HORIZON and OCEAN(a) trials. These would be the first approved therapies to specifically lower Lp(a).

References

• MedlinePlus: Lipoprotein(a)
• NIH: Lipoprotein(a) and cardiovascular risk
• Cleveland Clinic: High lipoprotein(a)
• CDC: About Lipoprotein (a)
• EAS 2022 consensus statement on Lp(a)
• ACC: Update on Lipoprotein(a)

Related Resources

• Lipoprotein(a) — Biomarker Overview
• How to Improve Your Lipoprotein(a) Naturally
• Lipoprotein(a): The Cardiovascular Risk Factor Most People Miss